NEW YORK, June 9, 2017 /PRNewswire/ --
On Thursday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session up 0.39%; the Dow Jones Industrial Average edged 0.04% higher; and the S&P 500 was up 0.03%. US markets saw a mixed session as 4 sectors closed in green, 3 sectors finished in red, and 2 sectors ended flat for the day. Pre-market today, DailyStockTracker.com reviews these four Biotechnology stocks: Soligenix Inc. (NASDAQ: SNGX), Sorrento Therapeutics Inc. (NASDAQ: SRNE), Alcobra Ltd (NASDAQ: ADHD), and Akebia Therapeutics Inc. (NASDAQ: AKBA). Access DailyStockTracker.com's free research reports for this morning's stocks line-up at:
On Thursday, shares in Princeton, New Jersey headquartered Soligenix Inc. recorded a trading volume of 167,699 shares. The stock ended the session 2.18% lower at $2.24. The Company's shares are trading 17.84% below their 50-day moving average. Moreover, shares of Soligenix, which focuses on developing and commercializing products to treat rare diseases in the US, have a Relative Strength Index (RSI) of 40.80. Free research report on SNGX is available at:
San Diego, California-based Sorrento Therapeutics Inc.'s stock closed the day 3.12% higher at $1.65. A total volume of 872,403 shares was traded, which was above their three months average volume of 841,160 shares. The Company's shares are trading 23.13% below their 50-day moving average. Additionally, shares of Sorrento Therapeutics, which engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide, have an RSI of 41.11.
On May 22nd, 2017, research firm Rodman & Renshaw reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $30 a share to $20 a share. The complimentary research report on SRNE can be downloaded at:
Shares in Tel Aviv, Israel headquartered Alcobra Ltd recorded a trading volume of 72,368 shares. The stock ended yesterday's trading session flat at $1.13. The Company's shares are trading below their 50-day moving average by 1.76%. Furthermore, shares of Alcobra, which focuses on the development and commercialization of proprietary pharmaceutical products, have an RSI of 46.48. Visit us today and access our complete research report on ADHD at:
Cambridge, Massachusetts headquartered Akebia Therapeutics Inc.'s stock finished Thursday's session 1.82% higher at $13.44 with a total trading volume of 218,070 shares. The Company's shares have advanced 8.04% in the last one month, 45.14% over the previous three months, and 29.11% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 15.49% and 38.41%, respectively. Additionally, shares of Akebia Therapeutics, which focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor biology, have an RSI of 56.57. Get free access to your research report on AKBA at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA